An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Cases of HIV amongst heterosexual patients in England has risen by more than 30% since 2022. Data from the UKHSA found that ...

Pre-exposure prophylaxis (PrEP) with antiretroviral medications is effective in preventing HIV infections. PrEP use has increased between 2013 and 2023. Multiple PrEP medications are available in ...

HIV groups have criticised a decision not to recommend a long-acting injectable form of PrEP (Pre-exposure prophylaxis ... (NICE), the body that publishes guidelines on which treatments should ...

Indigenous communities in Latin America say they are missing out on life-saving HIV drugs due to a lack of representation.

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...